Extracorporeal Membrane Oxygenation for COVID-19: Comparison of Outcomes to Non-COVID-19–Related Viral Acute Respiratory Distress Syndrome From the Extracorporeal Life Support Organization Registry
Autor: | Abhimanyu Chandel, MD, Nitin Puri, MD, FCCP, Emily Damuth, MD, Christopher Potestio, MD, Lars-Kristofer N. Peterson, MD, FACEP, FAAEM, Julia Ledane, BS, Craig R. Rackley, MD, Christopher S. King, MD, FCCP, Steven A. Conrad, MD, PhD, FFCM, MCCM, Adam Green, MD, MBA |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | Critical Care Explorations, Vol 5, Iss 2, p e0861 (2023) |
Druh dokumentu: | article |
ISSN: | 2639-8028 00000000 |
DOI: | 10.1097/CCE.0000000000000861 |
Popis: | OBJECTIVES:. To compare complications and mortality between patients that required extracorporeal membrane oxygenation (ECMO) support for acute respiratory distress syndrome (ARDS) due to COVID-19 and non-COVID-19 viral pathogens. DESIGN:. Retrospective observational cohort study. SETTING:. Adult patients in the Extracorporeal Life Support Organization registry. PATIENTS:. Nine-thousand two-hundred ninety-one patients that required ECMO for viral mediated ARDS between January 2017 and December 2021. INTERVENTIONS:. None. MEASUREMENTS AND MAIN RESULTS:. The primary outcomes of interest were mortality during ECMO support and prior to hospital discharge. Time-to-event analysis and logistic regression were used to compare outcomes between the groups. Among 9,291 included patients, 1,155 required ECMO for non-COVID-19 viral ARDS and 8,136 required ECMO for ARDS due to COVID-19. Patients with COVID-19 had longer duration of ECMO (19.6 d [interquartile range (IQR), 10.1–34.0 d] vs 10.7 d [IQR, 6.3–19.7 d]; p < 0.001), higher mortality during ECMO support (44.4% vs 27.5%; p < 0.001), and higher in-hospital mortality (50.2% vs 34.5%; p < 0.001). Further, patients with COVID-19 were more likely to experience mechanical and clinical complications (membrane lung failure, pneumothorax, intracranial hemorrhage, and superimposed infection). After adjusting for pre-ECMO disease severity, patients with COVID-19 were more than two times as likely to die in the hospital compared with patients with non-COVID-19 viral ARDS. CONCLUSIONS:. Patients with COVID-19 that require ECMO have longer duration of ECMO, more complications, and higher in-hospital mortality compared with patients with non-COVID-19–related viral ARDS. Further study in patients with COVID-19 is critical to identify the patient phenotype most likely to benefit from ECMO and to better define the role of ECMO in the management of this disease process. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |